You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
March-in mania
The White House today will take a long-awaited step to potentially broaden the government’s authority to undermine patents for medicines developed with taxpayer funding — including considering a drug’s price as one part of the framework, my co-author Sarah and I report.
The pharmaceutical industry has argued that the possibility of patents being invalidated creates instability in the funding pipeline. But it’s unclear whether the Biden administration is actually planning to use this authority at all in the next year.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect